Abstract | BACKGROUND: Bartonella henselae is a Gram-negative bacterium transmitted to humans by a scratch from cat in the presence of ectoparasites. Humans infected with B. henselae can result in various clinical diseases including local lymphadenopathy and more serious systemic disease such as persistent bacteremia and endocarditis. The current treatment of persistent B. henselae infections is not very effective and remains a challenge. To find more effective treatments for persistent and biofilm Bartonella infections, in this study, we evaluated a panel of drugs and drug combinations based on the current treatment and also promising hits identified from a recent drug screen against stationary phase and biofilm recovered cells of B. henselae. RESULTS: CONCLUSIONS: These findings may facilitate development of more effective treatment of persistent Bartonella infections in the future.
|
Authors | Xiaoyan Zheng, Xiao Ma, Tingting Li, Wanliang Shi, Ying Zhang |
Journal | BMC microbiology
(BMC Microbiol)
Vol. 20
Issue 1
Pg. 87
(04 10 2020)
ISSN: 1471-2180 [Electronic] England |
PMID | 32276590
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Analgesics
- Drug Combinations
- Gentamicins
- Ciprofloxacin
- Azithromycin
- Nitrofurantoin
- Methylene Blue
- Rifampin
|
Topics |
- Analgesics
(pharmacology)
- Azithromycin
(pharmacology)
- Bartonella henselae
(drug effects, physiology)
- Biofilms
(drug effects)
- Ciprofloxacin
(pharmacology)
- Drug Combinations
- Drug Therapy, Combination
- Gentamicins
(pharmacology)
- Methylene Blue
(pharmacology)
- Microbial Sensitivity Tests
- Microbial Viability
(drug effects)
- Nitrofurantoin
(pharmacology)
- Rifampin
(pharmacology)
|